Clinical Trial Update: Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating epoetin alfa with or without dexamethasone for fatigue and anemia in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Fatigue
• Prostate Cancer

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Anemia, Fatigue | Phase 3 | Status: COMPLETED